ArticleMolecular and clinical oncology2025
Seven-year survival with no recurrence after conversion surgery for pancreatic ductal adenocarcinoma with peritoneal metastasis treated with intraperitoneal and intravenous chemotherapy: A case report.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, particularly PDAC with peritoneal metastases. The present report describes a case of distal pancreatectomy (DP) following ip and iv chemotherapy for PDAC with peritoneal metastases, with long-term survival after CS. A 62-year-old man was referred to Tonan Hospital (Sapporo, Japan) for ip and iv chemotherapy after being diagnosed with unresectable pancreatic body adenocarcinoma with peritoneal dissemination at another hospital. The patient was administered four cycles of ip paclitaxel (ipPTX) plus ivPTX plus S-1, followed by four cycles of ipPTX plus fluorouracil plus leucovorin, irinotecan and oxaliplatin. After 9 months of preoperative treatment, the disappearance of peritoneal dissemination was confirmed; thus, the patient underwent DP. The histopathological diagnosis was ypT2, ypN0, ypM0 and ypStage IB, and the histologic response to chemotherapy was grade IIb, according to the Evans classification. Postoperative adjuvant chemotherapy including ipPTX was administered for 12 months. The patient survived without recurrence for 7 years after the CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.